-
An 84-year-old community-dwelling retired physician who maintains an active lifestyle and regularly attends community hospital meetings and lectures is seen for advice regarding management. He has a longstanding history of mild hypertension currently controlled by diet and hydrochlorothiazide.
-
Potentially operable patients with Stage I non-small cell lung cancer who were treated with stereotactic ablative radiotherapy (SABR) between 1993-2010 were retrospectively identified in a prospectively collected database. Despite the median age of 76 years and the median comorbidity score of 2 in these 177 potentially operable patients, the 3-year survival was 85%. Post-SABR 30-day mortality was 0%, while predicted 30-day mortality for a lobectomy, derived using the Thoracoscore predictive model, would have been 2.6%. Local control at 3 years was 93%.
-
Host-related immunoproliferation may contribute to the pathogenesis of certain clonal myeloid disorders such as myelofibrosis and myelodysplasia.
-
Two very recent publications address the management of newly diagnosed multiple myeloma. In the first, two bortezomib-containing three-drug regimens proved equally effective as a more complex four-drug regimen in achieving meaningful initial responses. The second demonstrated the value of maintenance lenalidomide for achieving longer progression-free survival.
-
The patient is a 56-year-old woman with known meningioma first resected in 1999 followed by external beam irradiation. In 2005, she developed progressive right leg weakness and had a second operation and course of radiation.
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
-
Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
-
-
Ipilimumab has recently been approved for the treatment of advanced melanoma. The current trial was undertaken to determine its safety and efficacy in patients with brain involvement.
-
Preclinical studies provide a rationale for examining a role for sunitinib in the treatment of breast cancer. However, in this large, multicenter trial, the combination of sunitinib with docetaxel did not prolong progression-free or overall survival when compared to docetaxel alone, and it appeared to be less well tolerated. The role for sunitinib remains to be established for the treatment of breast cancer.